RE:RE:RE:RE:Question for the Pharma SavvyRef: $250M for 33% of the company? I hope I misread that, and you meant as a buy-in with performance milestone payments for 1 single indication. A total buyout for the entire portfolio and all future development of the galaxy of cancer indications at one time? I don't think many would consider that b/c negotiations haven't run the full gammit of valuation possibilities, for the entire sum of cancer indications.
I'm more inclinded to think once the 1st partnership and performance milestones are established, any future indications would be worth multiples, depending on the targeted cancer indication. And then hopefully bidding wars for new targeted indications.
Vulture capitalists buyout weak companies and sell them off in pieces based on "best" value and how each individual division/asset matches to a potential buyer. The principal being that the sum total of the separate pieces are worth more than selling the weaker company's assets in 1 lump sum. Rarely do the entire stable of assets create maximum value to one buyer. I will admit this is cancer we're talking about and I'd be shocked if only 1 Pharma was interested in the spectrum of possibilities that can be addressed by Ruvidar.
I'm also betting that this new wave of laboratory testing of Ruvidar (as boosters or enhancements) to existing chemo drug treatments, is at the direction of Dr. Lbiati. Her most difficult challenge is getting an audience/1st meeting and the initial conversation has to have compelling potential. None more compelling than showing an enhancement of performance to "that particular company's" existing approved product.
Interesting times. I'm enjoying reading about TLT's spectrum of lab testing and results using Ruvidar.
Thank you to everyone that contributes to the valuable details presented on this board, through your personal research and work experiences.
GLTA, BK